Skip to Main Content

Richard Bucala, MD, PhD

Rheumatology, Pathology

Biography

Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health. He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally. Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF antibody developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders. He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project. 

Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

Titles

  • Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Microbial Diseases)
  • Chief, Rheumatology, Allergy, & Immunology
  • Rheumatologist in Chief, Rheumatology
  • Affiliated Faculty, Yale Institute for Global Health

Education & Training

  • Fellow
    Hospital for Special Surgery (1991)
  • Resident
    Brigham & Women's Hospital/Harvard Medical School (1988)
  • MD
    Cornell College (1986)
  • PhD
    Rockefeller University (1985)
  • Visiting Fellow
    Institut Pasteur, Paris (1985)
  • BS
    Yale University (1979)
  • MS
    Yale University (1979)

Additional Information

Biography

Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health. He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally. Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF antibody developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders. He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project. 

Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

Titles

  • Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Microbial Diseases)
  • Chief, Rheumatology, Allergy, & Immunology
  • Rheumatologist in Chief, Rheumatology
  • Affiliated Faculty, Yale Institute for Global Health

Education & Training

  • Fellow
    Hospital for Special Surgery (1991)
  • Resident
    Brigham & Women's Hospital/Harvard Medical School (1988)
  • MD
    Cornell College (1986)
  • PhD
    Rockefeller University (1985)
  • Visiting Fellow
    Institut Pasteur, Paris (1985)
  • BS
    Yale University (1979)
  • MS
    Yale University (1979)

Additional Information